A New Advancement in Retinal Care

Mississippi Retina Associates is now offering ENCELTO, a first-of-its-kind treatment designed to slow the progression of a rare retinal disease that can lead to permanent vision loss.

For adults living with macular telangiectasia type 2 (MacTel Type 2), the availability of ENCELTO represents an important advancement in retinal care. Approved by the U.S. Food and Drug Administration (FDA) in March 2025, ENCELTO is the first FDA-approved treatment specifically for this condition.

Understanding Macular Telangiectasia Type 2

MacTel Type 2 is a rare, progressive retinal disease that affects the macula, the central part of the retina responsible for sharp, detailed vision. As the condition progresses, patients may experience blurred or distorted central vision, difficulty reading, or trouble recognizing faces. Because changes can develop gradually, early detection and continued monitoring are important.

Until recently, patients with MacTel Type 2 had no FDA-approved treatment specifically designed to slow the disease’s progression.

How Does ENCELTO Work?

ENCELTO is an innovative, encapsulated cell-based gene therapy delivered through a small implant placed inside the eye during an outpatient surgical procedure. The implant contains specially engineered cells that continuously release ciliary neurotrophic factor (CNTF), a protein that helps support the health and survival of retinal cells.

By helping protect these cells, ENCELTO is designed to slow the progression of retinal degeneration associated with MacTel Type 2.

Clinical studies demonstrated that ENCELTO slowed the loss of light-sensitive retinal cells compared with a sham procedure, supporting its FDA approval.

Who May Benefit from ENCELTO?

ENCELTO is approved for adults diagnosed with idiopathic MacTel Type 2. The treatment is intended to slow disease progression rather than restore vision that has already been lost. As with any surgical treatment, there are potential risks, and not every patient will be an appropriate candidate.

A comprehensive retinal evaluation can help determine whether ENCELTO may be suitable based on a patient’s diagnosis, retinal health, and individual circumstances.

Advanced Retinal Treatments at Mississippi Retina Associates

At Mississippi Retina Associates, our commitment to preserving vision includes providing patients with access to advancements in retinal care.

With the addition of ENCELTO, our retinal specialists can offer a new treatment option for eligible adults living with MacTel Type 2.

If you have been diagnosed with MacTel Type 2 or are experiencing changes in your central vision, contact Mississippi Retina Associates at 601-981-4091 to learn more about scheduling a retinal evaluation.

Treatment eligibility and potential benefits and risks should be discussed with your retinal specialist.